Start-up project in the stem cell area is looking for a business economist

About
The spin-off project UriCell is looking for an energetic business economist with an entrepreneurial nature who will support the business development, product-market-fit, strategic and financial planning, securing follow-up financing and the acquisition of customers and partners.

UriCell is based at the Institute for Stem Cell Research and Regenerative Medicine at the University Hospital Düsseldorf and is currently funded by the EXIST transfer of research funding program. [https://www.uniklinik-duesseldorf.de/uricell](https://www.uniklinik-duesseldorf.de/uricell)

Customer Problem
Facing over 760 Mio. kidney patients globally, there is a high need for advanced cellular tools for kidney-related R&D. So far, genetically modified cells, animal cells or human cells obtained from invasive procedures such as biopsies are used for drug development, and toxicity testing. These cell types are associated with significant limitations.

Solution
Based on research from the last five years, the UriCell team can obtain high-quality kidney stem cells from urine samples. A three-staged business model is expected to generate new pre-clinical and clinical solutions. In the first stage, UriCell aims to sell cell products and associated data off-the-shelf and on-demand to Pharma companies, CROs an research institutes.

Unique Selling Propositions
- UriCell as first mover in commercializing urine derive kidney stem cells
- Enabling new R&D with increased predictive potential
- Non-invasive approach allows stem cell isolation from every individual
- Ideal for customer-specific approaches
- Selection of relevant cells from broad donor portfolio

Current Status & Achievements
- Funded by the EXIST-FT I program until October 2022
- Existing proof-of-concepts in the market:
  - Validation of urine-derived kidney stem cells for toxicity testing in 3 pilot projects with CROs
  - Successful generation of 2 iPSCs lines from urine-derived stem cells from patients carrying a genetic disease for a pilot customer
- Market launch of the kidney stem cell products and services is planned for 2022

Contact for further information and CVs: Dr. Lucas Spitzhorn, lucas-sebastian.spitzhorn@med.uni-duesseldorf.de